Sep 9, 2022
Verathon Response
3yHealthcare is an ever evolving industry. At Verathon we embrace that evolution and in 2019, we introduced our first ever consumable product with our single-use BFlex. As product portfolios change, often so does the structure of commission plans. However, our average At-Plan targets have not been impacted by the change and still remain in the 75th percentile of comparable medical device companies that we survey against every year. Additionally, our attrition is below the national average for sales at under 18%. Most of the recent departures indicated a desire to remain in a 100% capital equipment portfolio which their new role provided to them.
If you have any additional feedback, please email us at humanresources@verathon.com.